Cross-Tolerance of Recipient-Derived Transforming Growth Factor-Beta Dendritic Cells

M. M. Tiao; L. Lu; L. T. Huang; C. D. Liang; C. L. Chen; R. Tao; J. J. Fung; S. Qian

doi:10.1016/j.transproceed.2006.11.004

Cross-Tolerance of Recipient-Derived Transforming Growth Factor-Beta Dendritic Cells

M. M. Tiao, L. Lu, L. T. Huang, C. D. Liang, C. L. Chen, R. Tao, J. J. Fung, S. Qian^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

4 Scopus citations

Abstract

Administration of donor-derived immature dendritic cells (DC) treated with transforming growth factor-beta (TGF-β) to prevent allograft rejection is not applicable for clinical use. We therefore attempted to explore the use of recipient-derived DC pulsed with donor antigens via the indirect pathway (cross-priming). DC were propagated from C3H (H2^k) bone marrow (BM) using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). TGF-β (0.2 ng/mL) was added at the initiation of culture. The resultant TGF-β DC were pulsed with B10 (H2^b) splenocyte lysate. Expression of major histocompatibility complex (MHC) class I and II was not affected, while CD40, CD80, and CD86 costimulatory molecules on DC were significantly inhibited by treatment with TGF-β. C3H DC pulsed with B10 antigens stimulated a proliferative response in C3H T cells which was inhibited when DC were treated with TGF-β, and the cytotoxic T-lymphocyte (CTL) activity was also inhibited. This observation correlated with reduced interferon-gamma (IFN-γ) and increased IL-10 production. A single injection of TGF-β DC prolonged allograft survival (median survival time [MST] 18 days vs 10 days in no-DC treatment control; P < .05). These data indicated that an approach utilizing recipient DC as a "vaccine" strategy is possible.

Original language	English
Pages (from-to)	281-282
Number of pages	2
Journal	Transplantation Proceedings
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/j.transproceed.2006.11.004
State	Published - 01 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.transproceed.2006.11.004

Cite this

@article{9cc6b001c3b94b8d897c1b5b5eface59,

title = "Cross-Tolerance of Recipient-Derived Transforming Growth Factor-Beta Dendritic Cells",

abstract = "Administration of donor-derived immature dendritic cells (DC) treated with transforming growth factor-beta (TGF-β) to prevent allograft rejection is not applicable for clinical use. We therefore attempted to explore the use of recipient-derived DC pulsed with donor antigens via the indirect pathway (cross-priming). DC were propagated from C3H (H2k) bone marrow (BM) using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). TGF-β (0.2 ng/mL) was added at the initiation of culture. The resultant TGF-β DC were pulsed with B10 (H2b) splenocyte lysate. Expression of major histocompatibility complex (MHC) class I and II was not affected, while CD40, CD80, and CD86 costimulatory molecules on DC were significantly inhibited by treatment with TGF-β. C3H DC pulsed with B10 antigens stimulated a proliferative response in C3H T cells which was inhibited when DC were treated with TGF-β, and the cytotoxic T-lymphocyte (CTL) activity was also inhibited. This observation correlated with reduced interferon-gamma (IFN-γ) and increased IL-10 production. A single injection of TGF-β DC prolonged allograft survival (median survival time [MST] 18 days vs 10 days in no-DC treatment control; P < .05). These data indicated that an approach utilizing recipient DC as a {"}vaccine{"} strategy is possible.",

author = "Tiao, {M. M.} and L. Lu and Huang, {L. T.} and Liang, {C. D.} and Chen, {C. L.} and R. Tao and Fung, {J. J.} and S. Qian",

year = "2007",

month = jan,

doi = "10.1016/j.transproceed.2006.11.004",

language = "英语",

volume = "39",

pages = "281--282",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Cross-Tolerance of Recipient-Derived Transforming Growth Factor-Beta Dendritic Cells

AU - Tiao, M. M.

AU - Lu, L.

AU - Huang, L. T.

AU - Liang, C. D.

AU - Chen, C. L.

AU - Tao, R.

AU - Fung, J. J.

AU - Qian, S.

PY - 2007/1

Y1 - 2007/1

N2 - Administration of donor-derived immature dendritic cells (DC) treated with transforming growth factor-beta (TGF-β) to prevent allograft rejection is not applicable for clinical use. We therefore attempted to explore the use of recipient-derived DC pulsed with donor antigens via the indirect pathway (cross-priming). DC were propagated from C3H (H2k) bone marrow (BM) using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). TGF-β (0.2 ng/mL) was added at the initiation of culture. The resultant TGF-β DC were pulsed with B10 (H2b) splenocyte lysate. Expression of major histocompatibility complex (MHC) class I and II was not affected, while CD40, CD80, and CD86 costimulatory molecules on DC were significantly inhibited by treatment with TGF-β. C3H DC pulsed with B10 antigens stimulated a proliferative response in C3H T cells which was inhibited when DC were treated with TGF-β, and the cytotoxic T-lymphocyte (CTL) activity was also inhibited. This observation correlated with reduced interferon-gamma (IFN-γ) and increased IL-10 production. A single injection of TGF-β DC prolonged allograft survival (median survival time [MST] 18 days vs 10 days in no-DC treatment control; P < .05). These data indicated that an approach utilizing recipient DC as a "vaccine" strategy is possible.

AB - Administration of donor-derived immature dendritic cells (DC) treated with transforming growth factor-beta (TGF-β) to prevent allograft rejection is not applicable for clinical use. We therefore attempted to explore the use of recipient-derived DC pulsed with donor antigens via the indirect pathway (cross-priming). DC were propagated from C3H (H2k) bone marrow (BM) using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). TGF-β (0.2 ng/mL) was added at the initiation of culture. The resultant TGF-β DC were pulsed with B10 (H2b) splenocyte lysate. Expression of major histocompatibility complex (MHC) class I and II was not affected, while CD40, CD80, and CD86 costimulatory molecules on DC were significantly inhibited by treatment with TGF-β. C3H DC pulsed with B10 antigens stimulated a proliferative response in C3H T cells which was inhibited when DC were treated with TGF-β, and the cytotoxic T-lymphocyte (CTL) activity was also inhibited. This observation correlated with reduced interferon-gamma (IFN-γ) and increased IL-10 production. A single injection of TGF-β DC prolonged allograft survival (median survival time [MST] 18 days vs 10 days in no-DC treatment control; P < .05). These data indicated that an approach utilizing recipient DC as a "vaccine" strategy is possible.

UR - http://www.scopus.com/inward/record.url?scp=33846651267&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.11.004

DO - 10.1016/j.transproceed.2006.11.004

M3 - 文章

C2 - 17275522

AN - SCOPUS:33846651267

SN - 0041-1345

VL - 39

SP - 281

EP - 282

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 1

ER -

Cross-Tolerance of Recipient-Derived Transforming Growth Factor-Beta Dendritic Cells

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this